As enhanced mitochondrial fission and impaired fusion appear to contribute fundamentally to the inhibition of certain cancers, Drp1-mediated mitochondrial fission thus may represent a promising novel therapeutic target for cancers demonstrating excessive mitochondrial fission. This evidence concerns the gene DNM1L and cancer.